Seres Therapeutics (MCRB) FCF Margin (2016 - 2026)

Seres Therapeutics (MCRB) posted FCF Margin of 4569.83% for Q1 2026, down 35.8% sequentially from 3365.07% in Q4 2025.

Seres Therapeutics (MCRB) FCF Margin (2016 - 2026) Analysis & Trends

Seres Therapeutics has reported FCF Margin for 10 years, with the latest figure at 4569.83% in Q1 2026.

Quarterly FCF Margin changed N/A year-over-year to 4569.83% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 3692.24% (changed N/A YoY) and the FY2025 annual result came in at 109.63%, changed N/A from the prior year.
FCF Margin declined to 4569.83% in Q1 2026 per MCRB's latest filing, from 3365.07% in the prior quarter.
Over five years, FCF Margin peaked at 626.21% in Q3 2025 and troughed at 17523.87% in Q3 2023.
A 4-year average of 5100.58% and a median of 4472.7% in 2022 frame the typical range for FCF Margin.
The widest YoY moves for FCF Margin: up 581713 bps in 2023, down 1575764 bps in 2023.
Over 4 years, FCF Margin stood at 5779.79% in 2022, then soared by 101 bps to 37.34% in 2023, then plunged by 9112 bps to 3365.07% in 2025, then slumped by 36 bps to 4569.83% in 2026.
According to Business Quant data, FCF Margin over the past three periods registered 4569.83%, 3365.07%, and 626.21% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	138.41 Bn	130.56 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	86.12 Bn	78.12 Bn	3.93 Bn	13.35%
3	Argenx Se	64.41 Bn	59.23 Bn	1.37 Bn	-
4	Moderna	57.56 Bn	52.43 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	42.06 Bn	36.96 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	30.95 Bn	27.65 Bn	992.69 Mn	22.62%
7	BioNTech SE	27.48 Bn	9.09 Bn	668.28 Mn	41.07%
8	Insmed	27.31 Bn	26.15 Bn	358.27 Mn	-22.35%
9	Royalty Pharma	27.04 Bn	26.20 Bn	-	70.82%
10	Seres Therapeutics	43.87 Mn	43.87 Mn	-	-3,042.66%

Download Data